The long and arduous journey to regulate cannabidiol (CBD) in Europe, which began in 2018 with the European Union’s classification of CBD as a ‘novel food’, is now playing out in the courtrooms of the United States.
The UK’s first-ever CBD product authorisations, originally expected to be completed by Autumn 2026, could now face another setback as Food Standards Scotland (FSS) insists on holding its own consultation.
As part of the FSA’s re-energised efforts to push forward with the long-running CBD novel foods approvals process, the agency has continued to actively liaise with industry stakeholders regarding their applications.
The UK’s Medicines and Healthcare products Regulatory Agency (MHRA) and the Food Standards Agency (FSA) have both issued regulatory updates on CBD this week.
The UK’s long and troubled CBD novel foods approval process seems to be gaining some momentum, as numerous major companies have announced their progression to the final risk assessment stage.
In a long-awaited and major step forward for the UK’s CBD sector, the regulator has announced a new roadmap that could see the first products given official approval by Spring next year.
Last month, UK regulators held two key meetings on the future shape of novel foods regulation in the country, seeing many businesses hope that some much-needed clarity may be provided regarding the status of CBD.
BRITISH CANNABIS™ Submits Article 4 Application for Non-Novel Status of a Cannabis Ingredient and Receives a Preliminary Green Light.
PRESS RELEASE 22nd Century Group, Inc. (Nasdaq: XXII), a leading biotechnology company dedicated to improving health with reduced nicotine tobacco, hemp/cannabis and hops advanced plant technologies, today announced the acquisition of privately held RX Pharmatech Ltd (RXP), a leading United Kingdom distributor of cannabinoids with 1,276 novel food applications with the U.K.
